Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping

Mutations in the MET exon 14 RNA splice acceptor and donor sites, which lead to exon skipping, deletion of the juxtamembrane domain containing the Cbl E3-ubiquitin ligase binding site, and decreased turnover of the resultant aberrant MET protein, were previously reported to be oncogenic in preclinic...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Discov
Hlavní autoři: Paik, Paul K., Drilon, Alexander, Fan, Pang-Dian, Yu, Helena, Rekhtman, Natasha, Ginsberg, Michelle S., Borsu, Laetitia, Schultz, Nikolaus, Berger, Michael F., Rudin, Charles M., Ladanyi, Marc
Médium: Artigo
Jazyk:Inglês
Vydáno: 2015
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4658654/
https://ncbi.nlm.nih.gov/pubmed/25971939
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-14-1467
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky